4/A: AEON Biopharma Director Amends Filing to Correctly Report Stock Ownership

Robert J. Palmisano, a director at AEON Biopharma, files an amended Form 4 to correct an omission in a previous filing regarding shares held by The Palmisano Family, LLC and to report a grant of restricted stock units.

Summary

• Robert J. Palmisano, a director of AEON Biopharma, filed an amended Form 4 with the SEC.
• The amendment corrects an omission from a previous filing on September 4, 2024.
• The omitted information pertains to Class A Common Stock held by The Palmisano Family, LLC.
• The shares were distributed pro rata on July 19, 2024 (1,115,000 shares) and July 25, 2024 (1,150,000 shares).
• Palmisano also reported the acquisition of 36,021 restricted stock units on August 31, 2024, which vest in full on the second anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it primarily involves correcting a previous omission and reporting stock transactions.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The corrected filing provides shareholders with a more accurate view of insider ownership.
• The filing ensures compliance with SEC regulations, maintaining investor confidence.

Key Dates

Keywords

Form 4, amendment, AEON Biopharma, Palmisano, stock ownership, restricted stock units, Class A Common Stock, The Palmisano Family LLC